Roche Finance Report 2009

09

Roche Finance Report

Table of Contents

Roche Group Finance in brief Finance — 2009 in brief Financial Review Roche Group Consolidated Financial Statements Notes to the Roche Group Consolidated Financial Statements Report of Roche Management on Internal Control over Financial Reporting Report of the Statutory Auditor on the Consolidated Financial Statements Report of the Independent Auditor on Internal Control over Financial Reporting Multi-Year Overview and Supplementary Information Roche Securities Roche Holding Ltd, Basel Financial Statements Notes to the Financial Statements including Board and Executive remuneration disclosures as required by Swiss Law Appropriation of Available Earnings Report of the Statutory Auditor on the Financial Statements 2 2 3 4 30 36 125 126 128 130 136 138 138 140 142 148 149

2

Roche Finance Report 2009

Roche Group — Finance in brief

Finance in brief

Key results

Local sales growth % Operating profit margin before exceptional items, % of sales

Pharmaceuticals

2009

+10.9

36.3

2008 Diagnostics

2009

+4.7

+8.7

36.1

11.9

2008 Group

2009

+10.5

+10.5

12.3

30.6

2008

+5.9

30.5

2009 (mCHF)

2008 (mCHF)

(CHF)

% change (LC)

2009

% of sales 2008

Sales Research and development Operating profit before exceptional items Operating free cash flow Net income Net income attributable to Roche shareholders Free cash flow Core EPS (CHF) 1) Dividend per share 2) in CHF

49,051 9,874 15,012 15,722 8,510 7,784 8,893 12.19 6.00

45,617 8,845 13,896 12,378 10,844 8,969 4,979 11.04 5.00

+8 +12 +8 +27 –22 –13 +79 +10 +20

+10 +12 +14 +34 20.1 30.6 32.1 17.3 19.4 30.5 27.1 23.8

18.1 +20

10.9

31 December 2009

31 December 2008

% change (CHF)

Net cash (debt) Capitalisation — Debt — Equity

1) See page 134 for definition of Core EPS. 2) Proposed by the Board of Directors. LC = local currencies

(23,867) 51,830 42,416 9,414

16,682 57,911 4,089...